Anixa Biosciences, Inc. (ANIX)
Automate Your Wheel Strategy on ANIX
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANIX
- Rev/Share 0.0
- Book/Share 0.5191
- PB 6.2944
- Debt/Equity 0.0129
- CurrentRatio 9.3477
- ROIC -0.8006
- MktCap 112416739.0
- FreeCF/Share -0.2463
- PFCF -14.1761
- PE -9.0016
- Debt/Assets 0.0122
- DivYield 0
- ROE -0.5998
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ANIX | Maxim Group | -- | Buy | -- | $10 | March 21, 2025 |
News
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Read More
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose SAN JOSE, Calif. , June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.
Read More
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Read More
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , June 3, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine.
Read More
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , June 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine.
Read More
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today released a letter to shareholders from Chairman and CEO Dr. Amit Kumar, detailing significant progress across its programs and outlining key milestones for the remainder of the year.
Read More
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois.
Read More
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C.
Read More
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
Read More
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif. , March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.
Read More
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology.
Read More
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.
Read More
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently featured in Breaking Cancer News in an article titled "Navigating Uncharted Territory: CAR-T for Ovarian Cancer.
Read More
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif. , Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt Cancer Center ("Moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy for the treatment of ovarian cancer (NCT05316129).
Read More
Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
SAN JOSE, Calif. , Feb. 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured in an interview with Alpha Wolf Trading.
Read More
About Anixa Biosciences, Inc. (ANIX)
- IPO Date 1983-10-07
- Website https://www.anixa.com
- Industry Biotechnology
- CEO Dr. Amit Kumar Ph.D.
- Employees 5